首页> 外国专利> CD20-SPECIFIC REDIRECTED T CELLS AND THEIR USE IN CELLULAR IMMUNOTHERAPY OF CD20+ MALIGNANCIES

CD20-SPECIFIC REDIRECTED T CELLS AND THEIR USE IN CELLULAR IMMUNOTHERAPY OF CD20+ MALIGNANCIES

机译:CD20特异性重定向的T细胞及其在CD20 +恶性肿瘤细胞免疫治疗中的用途

摘要

Genetically engineered, CD20-specific redirected T cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CD20, an intracellular signaling domain, and a transmembrane domain. Use of such cells for cellular immunotherapy of CD20+ malignancies and for abrogating any untoward B cell function. In one embodiment, the cell surface protein is a single chain FvFc: zeta receptor where Fv designates the VH and VL chains of a single chain monoclonal antibody to CD20 linked by peptide, Fc represents a hinge-CH2-CH3 region of a human IgG1, and zeta represents the intracellular signaling domain of the zeta chain of human CD3. A method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.
机译:经过基因工程改造的CD20特异性重定向T细胞,表达的细胞表面蛋白具有胞外域,该域包含对CD20具有特异性的受体,胞内信号传导域和跨膜域。此类细胞用于CD20 +恶性肿瘤的细胞免疫治疗和消除任何不良的B细胞功能的用途。在一个实施方案中,细胞表面蛋白是单链FvFc:zeta受体,其中Fv表示通过肽连接的针对CD20的单链单克隆抗体的VH和VL链,Fc代表人IgG1的铰链-CH2-CH3区域, zeta代表人CD3的zeta链的胞内信号传导域。一种使用编码受体的裸露的DNA通过电穿孔制备表达嵌合T细胞受体的重定向T细胞的方法。

著录项

  • 公开/公告号WO0023573A3

    专利类型

  • 公开/公告日2000-09-08

    原文格式PDF

  • 申请/专利权人 CITY OF HOPE;

    申请/专利号WO1999US24484

  • 申请日1999-10-20

  • 分类号C12N5/10;C12N15/62;C12N15/85;A61K48/00;A61P35/00;

  • 国家 WO

  • 入库时间 2022-08-22 01:50:31

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号